
Sirtuin Agonists as Pan Influenza AntiviralsAward last edited on: 10/8/2021
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$2,304,858Award Phase
2Solicitation Topic Code
NIAIDPrincipal Investigator
Stacy W RemiszewskiCompany Information
Evrys Bio LLC (AKA: Forge Life Sciences LLC)
3805 Old Easton Road
Doylestown, PA 18902
Doylestown, PA 18902
(267) 893-6755 |
business@evrysbio.com |
www.forgelifescience.com |
Location: Single
Congr. District: 01
County: Bucks
Congr. District: 01
County: Bucks
Phase I
Contract Number: 1R44AI122488-01Start Date: 8/8/2016 Completed: 7/31/2017
Phase I year
2016Phase I Amount
$304,858Public Health Relevance Statement:
Public Health Relevance:
Seasonal flu annually causes considerable morbidity and mortality; its overall burden to the U.S. economy is estimated to be $83B per year. FORGE Life Science is developing antiviral drugs that boost a patient's own innate cellular defense against the flu-causing virus, influenza A, by activating viral restriction factors of the human host cell when infected by virus. Compared to current anti-influenza drugs, FORGE antivirals will provide an advanced therapeutic option in treatment of flu by (1) providing protection against a wide-range of flu-causing virus-types, influenza A and B, strains both sensitive and resistant to existing flu antivirals; and by (2) greatly reducing acquired viral-resistance.
Project Terms:
Address; Agonist; Amantadine; anti-influenza; anti-influenza drug; Antiviral Agents; Attenuated; Bacteriophages; base; Biological Availability; Biological Sciences; Cell Culture Techniques; Cell Cycle; Cells; Chemicals; Clinical; commercialization; Cytomegalovirus; Development; DNA Viruses; Dose; Drug Exposure; Drug Kinetics; Drug resistance; Enzyme Activation; Exhibits; Family; Ferrets; flu; Future; Genetic; Genome; Goals; Grant; Growth; Human; improved; In Vitro; in vitro activity; in vivo; Influenza; Influenza A virus; Influenza B Virus; Influenza Therapeutic; influenzavirus; Lead; lead series; Legal patent; Literature; Longevity; Lung; man; Marketing; Medical; meetings; Metabolic; Metabolism; Modeling; Monitor; Morbidity - disease rate; mortality; mouse model; Mus; Mutation; novel therapeutics; Oral; Oseltamivir; pandemic disease; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Plants; Plasma; polyphenol; Population; prevent; Property; public health relevance; Publishing; Regimen; Reporting; Research; research study; Resistance; Resistance development; Resistance profile; resistant strain; respiratory; Resveratrol; scaffold; seasonal influenza; Seasons; Serial Passage; Series; Sirtuins; small molecule; standard of care; Structure-Activity Relationship; Symptoms; Testing; Therapeutic; Therapeutic Index; Time; tool; Triage; Vaccines; Variant; Variation (Genetics); Viral; Viral Proteins; viral resistance; Virulent; Virus; Virus Replication
Phase II
Contract Number: 4R44AI122488-02Start Date: 8/8/2016 Completed: 7/31/2020
Phase II year
2018(last award dollars: 2019)
Phase II Amount
$2,000,000Public Health Relevance Statement:
Public Health Relevance:
Seasonal flu annually causes considerable morbidity and mortality; its overall burden to the U.S. economy is estimated to be $83B per year. FORGE Life Science is developing antiviral drugs that boost a patient's own innate cellular defense against the flu-causing virus, influenza A, by activating viral restriction factors of the human host cell when infected by virus. Compared to current anti-influenza drugs, FORGE antivirals will provide an advanced therapeutic option in treatment of flu by (1) providing protection against a wide-range of flu-causing virus-types, influenza A and B, strains both sensitive and resistant to existing flu antivirals; and by (2) greatly reducing acquired viral-resistance.
Project Terms:
Address; Agonist; Amantadine; anti-influenza; anti-influenza drug; anti-viral efficacy; Antiviral Agents; Attenuated; Bacteriophages; base; Biological Availability; Biological Sciences; Cell Culture Techniques; Cell Cycle; Cells; Chemicals; clinical development; clinical predictors; commercialization; comparative efficacy; Cytomegalovirus; Development; DNA Viruses; Dose; Drug Exposure; Drug Kinetics; Drug resistance; Enzyme Activation; Exhibits; experimental study; Family; Ferrets; flu; Future; Genetic; Genetic Variation; Genome; Goals; Grant; Growth; Human; improved; In Vitro; in vitro activity; in vivo; Influenza; Influenza A virus; Influenza B Virus; Influenza Therapeutic; influenzavirus; Investigation; Lead; lead optimization; lead series; Legal patent; Literature; Longevity; Lung; man; Medical; Metabolic; Metabolism; Modeling; Monitor; Morbidity - disease rate; mortality; mouse model; Mus; Mutation; novel therapeutics; Oral; Oseltamivir; pandemic disease; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology; Phase; Plants; Plasma; polyphenol; Population; prevent; Property; public health relevance; Publishing; Regimen; Reporting; Research; Resistance; Resistance development; Resistance profile; resistant strain; respiratory; Resveratrol; scaffold; seasonal influenza; Seasons; Serial Passage; Series; SIRT1 gene; Sirtuins; small molecule; standard of care; Structure-Activity Relationship; Symptoms; synergism; Testing; Therapeutic; Therapeutic Index; Time; tool; Triage; Vaccines; Variant; Viral; Viral Proteins; viral resistance; Virulent; Virus; virus development; Virus Replication